Posted by Michael Wonder on 07 Jan 2026
Biosplice announces the submission of its new drug application to the FDA for lorecivivint to treat knee osteoarthritis
6 January 2026 - Biosplice Therapeutics announced today that it has submitted its new drug application to the FDA for approval of its novel therapy for the treatment of knee osteoarthritis.
Biosplice’s drug candidate, lorecivivint, is a small-molecule suspension intended to be injected 1-2 times per year into the knee joint.
